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Background The aim was to compare resource utilization across the four health
trusts within the Western Norway Regional Health Authority since the establish-
ment of positron emission tomography (PET) at Haukeland University Hospital in
Bergen in 2009.
Methods Metadata from all PET examinations from 2009 to 2014 were
automatically imported from the PET centre’s central production database into a
custom-developed database system, MDCake. A PET examination was defined as a
procedure based on a single injection of radioactive tracer. The patients’ place of
residence and tentative diagnosis were coded based on the available clinical infor-
mation.
Results The total number of PET examinations increased from 293 in 2009 to
1616 in 2014. The number of PET examinations per year increased across all
diagnostic groups, but plateaued for lung cancer, gastrointestinal cancer and
malignant melanoma since 2013. The number of examinations per capita was
evenly distributed between the three northern health trusts with an average of
1260 PET studies per million inhabitants in 2014. However, patients residing in
the most southerly health trust received between 44% (2010) and 27% (2014;
P<0001, repeated measures ANOVA) fewer examinations per capita per year.
Conclusion Centralized PET in the Western Norwegian health region meets the cur-
rent clinical demand for patients residing in the three northern health trusts while
patients from the most southern health trust receive approximately 30% fewer
PET examinations. Access to specialized health care should be monitored routinely
in order to identify inequalities in referral patterns and resource utilization.
Introduction
Positron emission tomography (PET) was established as a
useful method for (re-)staging solid malignant tumours
already in the late 1990s (Reske & Kotzerke, 2001; Fletcher
et al., 2008). Compared with other Scandinavian countries,
PET was introduced to Norway relatively late (Norderhaug
et al., 2011). The first two dedicated PET/computed tomog-
raphy (CT) scanners were installed at Oslo University
Hospital (OUH) in 2005 and 2006. The country’s third
scanner was established by the Western Norway Regional
Health Authority (Helse Vest RHF; ‘Western Health Region’)
and Bergen Health Trust (Helse Bergen HF) at Haukeland
University Hospital (HUH) in Bergen in 2009. Since late
2013 PET/CT scanners are available in all four Norwegian
health regions (Fig. 1).
The PET-centre at HUH serves the entire Western Health
Region with a population of 11 million coming from four
different health trusts (Fig. 1). Since 2009, we have systemat-
ically monitored our production of PET examinations in
respect to referring institutions and disease groups as part of
our internal quality control. Our key questions were: Does
the PET centre in Bergen meet the clinical demand in
respect to the different diagnostic groups? And: Do patients
in the Western Health Region have equal access to PET
examinations?
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Methods
The first PET/CT in Bergen was performed on 29 April 2009.
Initially, F-18-fluorodeoxyglucose (FDG) was delivered by
plane from GE Healthcare in Oslo. Since Good Manufacturing
Practice (GMP) certification in March 2011, FDG is routinely
produced in the centre’s own radiopharmaceutical production
facility. In addition to FDG, anti-1-amino-3-[18F]fluorocyclo-
butyl-1-carboxylic acid (FACBC) produced by GE Healthcare
has been available for prostate cancer imaging since late 2014.
PET examinations in Norway are reimbursed by public health
care. As a rule, referrals to PET examinations are limited to
the specialist health service.
The study includes all FDG PET examinations conducted at
Bergen PET-centre between 29 April 2009 and 31 December
2014. For the purpose of this study, a dedicated application
was implemented under MDCake, our self-developed open
source client-server database for biomedical research (Bier-
mann, 2014; Biermann et al., 2015). As part of the general
imaging and image reading workflow, all image data acquired
at Bergen PET-centre are routinely transferred to the centre’s
central DICOM (Digital Imaging and Communications in Med-
icine) server (Segami Oasis 1.9.x; Segami Corporation, Colum-
bia, MD, USA). A link was set up between the central DICOM
server and MDCake by means of a special automatic import
module implemented in PHP (http://php.net). On import
into MDCake, data were automatically anonymized and given
unique check sums to eliminate data duplication. All imported
datasets were verified against the department’s Radiology
Information System (RIS) (Agfa HealthCare NV, Mortsel, Bel-
gium). For each patient examination the following items were
manually entered into the MDCake database: the postcode of
the patient’s place of residence at the time of the PET exami-
nation and the tentative clinical diagnosis coded according to
the International Classification of Diseases version 10 (ICD-10)
based on the available clinical information. In case of a PET
examination encompassing several DICOM studies (e.g. con-
trast-enhanced PET/CT head/neck in addition to a PET/CT of
the torso), the studies with the lowest resolution CTs were
marked as ‘hidden’ in MDCake to eliminate duplicate counting
in the analysis.
In the context of this analysis, a PET examination is a com-
plete imaging procedure based on a single injection of
radioactive drug in one patient regardless of the number of
acquired DICOM studies or series. Population figures are from
1 April 2014 (Statistics Norway, https://www.ssb.no/). Data
analysis was performed using the statistical program R (Bier-
mann, 2014; R Core Team, 2015). To detect differences
between different patient groups over time, the time series
were normalized on the production year 2014, and analysis
of variance (repeated measures ANOVA) was performed com-
plemented by Tukey’s method with a significance level of 5%
(two-sided). The project was conducted as a quality surveil-
lance study in full accordance with the guidelines issued by
the institutional review board (IRB) and current Norwegian
legislation.
To supplement the data from our own institution, we con-
ducted a national survey in February 2015, asking all institu-
tions providing PET in Norway for the number of PET
examinations (defined as tracer injections) per tracer per year.
Results
Since the introduction of PET at OUH in 2005, the number of
PET examinations performed in Norway increased from 80 in
2005 to 7525 in 2014 (Fig. 2). At Bergen PET-centre, the
number of examinations rose from 293 in 2009 to 1616 in
2014 (Fig. 2). All four health trusts contributed to the
increase (Fig. 3). Patients residing in the Bergen, Fonna, and
Førde Health Trusts underwent between 463 (2010) and
1260 (2014) PET examinations per million inhabitants per
year (Fig. 4). The frequency of PET examinations for patients
residing in Stavanger Health Trust was consistently between
27 to 44% lower (P<0001) compared to the other three
(Fig. 4). Ninety percent of all PET examinations concerned
malignant disease. Patients with gastrointestinal cancer (mainly
colorectal cancer) and lung cancer comprised the two largest
diagnostic groups (Fig. 5). The number of PET examinations
in both these groups as well as for patients with malignant
melanoma has remained stable since 2013, while demand in
the other diagnostic groups is still increasing. A total of 163
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Figure 1 PET scanners and health regions in Norway. The Northern
Region (Tromsø; 1 PET/CT) has a population of 454 000, the Central
Region (Trondheim; 1 PET/CT and 1 PET/MR) 663 000, and the
South Eastern Region (Oslo; 4 PET/CT) 281 millions. The Western
Health Region (1 PET/CT; 107 millions) is divided into four Health
Trusts: Førde (109 000 inhabitants), Bergen (434 000), Fonna
(178 000) and Stavanger (352 000).
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PET examinations were conducted for planning of external
beam radiation therapy, 67 of these in 2014.
Discussion
The number of PET examinations per capita per year varies
widely between different countries and regions: In Japan, 295
institutes performed 505 990 PET-CT examinations in 2012,
amounting to 5500 PET examinations per million inhabitants
per year (Kinuya et al., 2014). In Europe, 551 PET/CT cameras
produced about 900 000 examinations in the same year, aver-
aging approximately 1200 examinations per million per year in
2012 (European Association of Nuclear Medicine, Status of Nuclear
Medicine 2012, e-mail 13 July 2015). In Denmark, Norway’s
southern neighbour, 27 776 PET examinations were acquired
in 2011, amounting to approximately 4900 per million per year
(Danish Institute of Radiation Protection, 2012). Our own
national survey documented 7525 PET examinations in Norway
in 2014, 1500 per million per year. Thus, use of PET in Norway
has at last reached European standard (Norderhaug et al., 2011)
while Denmark is closer to Japanese practice.
Publications on production data from single institutions are
scarce. Odense Hospital, which serves a region with a popula-
tion of 12 million in central Denmark, published data on the
upstart of their own PET-centre. However, they focused their
analyses on diagnostic groups and outcomes and did not
examine the distribution of PET studies inside their geo-
graphic area (Høilund-Carlsen et al., 2011). Compared with
Denmark, Norway is a thinly populated country. While Nor-
wegian scenery is spectacular, transportation is difficult along
narrow winding roads and a jagged coastline. Patients from
the more remote parts of our health region may travel for up
to 5 h, often necessitating an overnight stay in Bergen. The
majority of patients from the southernmost locations travel to
Bergen by air.
Thus in Norway, the question of equal access to health care
has a strong geographical component. To our knowledge, our
study is the first to systematically examine the influence of the
place of residence on access to advanced diagnostics at a
regional centre. Our analysis revealed that patients from the
southernmost health trust had approximately 30% less chance
of obtaining a PET examination than the patients from the
three northern health trusts (Fig. 4). We became aware of this
geographic imbalance in our health region as early as 2010
and have tried to establish equal access to PET examinations
by providing information and lectures to our clinical partners
at Stavanger University Hospital as well as by prioritizing
patients from distant locations when allocating appointments.
However, the analysis over time shows that our efforts have
only partially succeeded (Fig. 4). The reasons for this regional
imbalance are difficult to ascertain. Geographical distance
provides no sufficient explanation in the context of Western
Norway. Travelling times from the northern parts of our own
health region are considerably longer than airplane travel from
0
2000
4000
6000
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Year
n
 
e
xa
m
in
at
io
ns New tracers
Aleris Oslo
St. Olavs
UNN
Haukeland
OUH
Figure 2 Number of PET examinations in
Norway from 2005 to 2014. The main col-
umns indicate the number of F-18-FDG-PET-
examinations at the different institutions (for
Aleris, a private institute in Oslo, only patients
with public reimbursement). The category
‘New tracers’ includes sodium fluoride (2012:
OUH 32, 2014: OUH 29, Aleris 2), F18-
FACBC (2012: OUH 24, 2013: OUH 193,
2014: OUH 225, Aleris 159, HUH 25), and
F-18-FDOPA (2013: OUH 3, 2014: OUH
22).
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Figure 3 Number of PET examinations at
Bergen PET-centre according to health trust.
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Figure 4 Number of PET examinations at
Bergen PET-centre per one million inhabitants
per half year for each of the four health
trusts.
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Stavanger. While a recent publication from Northern Norway
concluded that long distance travel reduced the frequency of
PET examination in lymphoma patients (Norum et al., 2015),
we found an inverse correlation between length of travel and
use of PET in sarcoma patients treated in Bergen and in Oslo
in a recent national population-based survey (Johnsen et al.,
2015). The most probable reason is thus a different referral
pattern at Stavanger University Hospital. Whether PET referrals
are restricted because of budgetary concerns is difficult to sur-
mise. It will be interesting to see if the use of PET across the
Western Health region will equalize when Stavanger Univer-
sity Hospital establishes its own PET-scanner late in 2016.
Several other hospitals outside the Western Health Region
have begun to establish their own PET scanners. A political
signal that uncontrolled development of PET capacity is not
desired, may be the cut in the reimbursements for PET exami-
nations for outpatients from approximately € 1400 to € 600
in summer 2014 (Directive for reimbursement for health ser-
vices, 2014). Given the thin population density and the neces-
sity of transporting radionuclides by air, small decentralized
PET units are difficult to run efficiently in Norway. Our data
show that a single centralized PET facility can serve a wide
area, providing patients equal access to advanced health care.
Considering the wide spectrum of PET examination fre-
quencies between countries like Japan and Denmark and the
rest of Europe, it is difficult to ascertain in how far PET at our
centre meets the clinical demand. More than 95% of all
patients get appointments within the time frame set by the
referring physician. The plateau in examination numbers for
gastrointestinal cancer, lung cancer and malignant melanoma
since 2013 indicates that the clinical demand is met for these
indications, at least in the context of current therapies. How-
ever, examination numbers continue to rise for most other
diagnostic groups, and we are planning to scale up our
production in the near future.
Limitations
(i) The study did not examine patient outcomes. While fol-
low-up information for patients residing in the Bergen Health
Trust would have been available through the electronic patient
journal (EPJ), routine access to the EPJ in the other three
trusts from our hospital is blocked. Outcome analysis would
thus have introduced bias into our survey. (ii) For similar rea-
sons, we did not attempt to evaluate the quality of referral
practice in the different health trusts. (iii) Detailed analyses of
the frequency of PET examinations between municipalities are
limited by the wide variation in population size ranging from
215 (Utsira) to 271949 (Bergen). (iv) We cannot provide
data on the lag time between referral and the actual PET
examination for patients from the different health trusts.
Although the information is stored in the department’s RIS,
this information cannot be retrieved. The lack of a suitable
analysis module prompted us to develop our own solution
under MDCake. (v) We have no data on how many patients
from the Stavanger Health Trust have undergone PET-exami-
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Figure 5 PET examinations at Bergen PET-
centre per diagnostic group. CUP = Carci-
noma of unknown primary, ENT = Ear, nose
& throat and thyroid cancer, Uro = urology
and gynaecological cancer, ‘Other’ = lym-
phadenopathy and suspected paraneoplastic
disease, GIT = gastrointestinal tract cancer.
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nations at other institutions than our own PET centre, but Sta-
vanger University Hospital confirms that the number is low.
Conclusion
Centralized PET in the Western Norwegian health region
meets the current clinical demand for patients resident in the
three Northern health trusts while there was a relative under-
use of PET in the most Southern health trust. Access to spe-
cialized health care should be monitored routinely in order to
identify inequalities in referral patterns and resource
utilization.
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